OnCofirm Rapid Cancer Tests electronic cassette reader
|

OncoFirm™ Electronic Reader

OncoFirm™ Electronic Reader cassette reader* (detailed information coming soon)…

Cutting-Edge Digital Cancer Diagnostics Solutions

  • Lateral Flow Assay Cancer Diagnostics
  • Qualitative and Quantitative Results
  • High Resolution Spectrometric Sensor
  • Fluorescence and Colorimetric
  • Cloud-based Algorithms for Boost Performance

Lateral Flow Electronic Reader (LFER) technology is an advanced diagnostic tool used to enhance and quantify results from lateral flow assays (LFAs), which are common in rapid tests like pregnancy or COVID-19 tests. While traditional LFAs are visual (relying on colored lines visible to the naked eye), electronic readers provide quantitative, objective, and often more sensitive results.

🔬 What is a Lateral Flow Electronic Reader?

A lateral flow electronic reader is a portable or benchtop device that interprets test strip results using optical, electrochemical, or fluorescence detection. These readers are designed to improve the accuracy, reproducibility, and traceability of LFA results.


⚙️ How It Works

  1. Sample runs through a test strip, just like in traditional LFAs.
  2. Signal generation: Instead of just colored lines, signal labels (like gold nanoparticles, fluorescent dyes, or electrochemical markers) produce a measurable signal.
  3. Electronic detection: The reader detects this signal using one of the following:
    • Optical sensors (e.g., photodiodes, CCD cameras)
    • Fluorescence detectors
    • Electrochemical sensors
  4. Data output: The signal is converted into a quantitative value displayed on a screen or sent to a connected device (e.g., smartphone or cloud system).

📦 Key Technologies Used in LFERs

  • Gold nanoparticle-based optical detection (most common)
  • Quantum dot fluorescence for high sensitivity
  • Electrochemical detection using screen-printed electrodes
  • Magnetic nanoparticles with magneto-resistive sensors
  • Smartphone integration for field diagnostics and data logging

Advantages

  • Quantitative results vs. qualitative visual lines
  • Higher sensitivity and lower detection limits
  • Reduced subjectivity and human error
  • Data connectivity: often Bluetooth or Wi-Fi enabled
  • Time-stamping and record-keeping for clinical settings

🧪 Applications

  • Medical diagnostics (e.g., infectious diseases, cancer biomarkers, hormones)
  • Veterinary and agricultural testing
  • Food safety and environmental monitoring
  • Biomarker quantification (e.g., CRP, PSA, CA125, CA72-4)

Similar Posts

  • OncoScreen-CEA

    OncoScreen-CEA Rapid Test for Carcinoembryonic Antigen (CEA) – Colorectal, Breast, Lung, and Pancreatic Cancer Screening Overview:OncoScreen-CEA is a rapid diagnostic test developed by OncoFirm Diagnostics for the detection and monitoring of Carcinoembryonic Antigen (CEA), a well-established biomarker associated with colorectal cancer and other solid tumors, including breast, lung, and pancreatic cancers. Built on our advanced…

  • OncoScreen-L

    OncoScreen-L Rapid Test Panel for Early Lung Cancer Detection Overview:OncoScreen-L is a cutting-edge rapid diagnostic panel developed by OncoFirm Diagnostics, designed to support the early detection of lung cancer in clinical settings. Utilizing lateral flow assay (LFA) technology enhanced with TF and Gal-GalNAc antigens, this test provides fast, accurate, and non-invasive screening—empowering healthcare professionals to…

  • OncoScreen-PSA

    OncoScreen-PSA Rapid Test for Prostate-Specific Antigen (PSA) Detection Overview:OncoScreen-PSA is a fast, reliable, and easy-to-use rapid test for the detection of elevated Prostate-Specific Antigen (PSA) levels—an important biomarker in the early identification and monitoring of prostate cancer. Developed using OncoFirm’s advanced lateral flow assay (LFA) technology, this test provides results within 15 minutes, empowering healthcare…

  • OncoMultiDx

    OncoMultiDx Multiplex Rapid Test for Multi-Cancer Screening in a Single Assay Overview:OncoMultiDx is OncoFirm Diagnostics’ most advanced lateral flow assay, designed to detect multiple cancer types from a single sample—providing a comprehensive, rapid, and non-invasive cancer screening tool for clinical environments. Utilizing a proprietary combination of TF and Gal-GalNAc antigens, along with enhanced nanoparticle signal…

  • RNA Polymerase II Levels in Histone Genes: A Predictive Biomarker for Tumor Aggressiveness and Recurrence

    RNA Polymerase II Levels in Histone Genes: A Predictive Biomarker for Tumor Aggressiveness and Recurrence Introduction Histone genes play a fundamental role in DNA packaging and chromatin structure, and their expression is tightly regulated during the cell cycle, particularly in S-phase. RNA Polymerase II (RNAPII), the enzyme responsible for transcribing protein-coding genes, including replication-dependent histone…

  • OncoScreen-B

    OncoScreen-B Rapid Test for Breast and Ovarian Cancer Detection Overview:OncoScreen-B is an advanced rapid diagnostic test developed by OncoFirm Diagnostics for the early detection of breast and ovarian cancers. Powered by proprietary lateral flow assay (LFA) technology, this test targets tumor-specific Thomsen-Friedenreich (TF) and Gal-GalNAc antigens, offering accurate, non-invasive cancer screening at the point of…